We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.47%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$31.4B
AUM Growth
-$3.29B
(-9.5%)
Cap. Flow
-$3.23B
Cap. Flow
% of AUM
-10.31%
Top 10 Holdings %
Top 10 Hldgs %
14.1%
Holding
3,232
New
197
Increased
1,216
Reduced
1,615
Closed
190
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aptiv
APTV
|
+$16.8M |
| 2 |
CMCSK
COMCAST CORP SPL A (NEW)
CMCSK
|
+$11.8M |
| 3 |
Hilton Worldwide
HLT
|
+$9.58M |
| 4 |
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
|
+$7.6M |
| 5 |
WEC Energy
WEC
|
+$6.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$215M |
| 2 |
Microsoft
MSFT
|
+$101M |
| 3 |
ExxonMobil
XOM
|
+$83.8M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$72.7M |
| 5 |
Johnson & Johnson
JNJ
|
+$68.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.19% |
| 2 | Healthcare | 14.93% |
| 3 | Technology | 14.47% |
| 4 | Industrials | 10.76% |
| 5 | Consumer Discretionary | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
AngioDynamics
ANGO
$611M
| $615K | ﹤0.01% |
37,522
-1,130
| -3% | -$18.8K |
|
2202
Kforce
KFRC
$1.02B
| $613K | ﹤0.01% |
26,820
-2,325
| -8% | -$51.7K |
|
|
EGRX
2203
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $611K | ﹤0.01% |
+7,555
| New | +$492K |
|
|
MIG
2204
DELISTED
MEADOWBROOK INSURANCE GRP INC
MIG
| $610K | ﹤0.01% |
70,959
-5,570
| -7% | -$47.6K |
|
|
REGI
2205
DELISTED
Renewable Energy Group, Inc.
REGI
| $610K | ﹤0.01% |
52,787
+7,540
| +17% | +$77.3K |
|
2206
US Physical Therapy
USPH
$1.2B
| $608K | ﹤0.01% |
11,111
-1,115
| -9% | -$55.2K |
|
2207
FormFactor
FORM
$8.28B
| $603K | ﹤0.01% |
65,521
-13,255
| -17% | -$120K |
|
|
EXAR
2208
DELISTED
Exar Corporation
EXAR
| $603K | ﹤0.01% |
61,618
-4,340
| -7% | -$45.4K |
|
|
RTEC
2209
DELISTED
Rudolph Technologies Inc
RTEC
| $602K | ﹤0.01% |
50,166
-3,840
| -7% | -$48K |
|
|
SHOE
2210
Shoe Station Group
SHOE
$413M
| $600K | ﹤0.01% |
41,552
-4,320
| -9% | -$60.5K |
|
2211
Geron
GERN
$828M
| $597K | ﹤0.01% |
139,544
-77,380
| -36% | -$307K |
|
2212
Mizuho Financial
MFG
$127B
| $597K | ﹤0.01% |
137,615
-79,400
| -37% | -$319K |
|
2213
Omeros
OMER
$857M
| $597K | ﹤0.01% |
33,168
-1,895
| -5% | -$40.9K |
|
2214
Standard BioTools
LAB
$340M
| $596K | ﹤0.01% |
24,615
-1,560
| -6% | -$49.2K |
|
2215
Inogen
INGN
$175M
| $594K | ﹤0.01% |
+13,320
| New | +$511K |
|
2216
Tempest Therapeutics
TPST
$13.7M
| $594K | ﹤0.01% |
7
-1
| -13% | -$91.6K |
|
|
EPZM
2217
DELISTED
Epizyme, Inc
EPZM
| $594K | ﹤0.01% |
24,760
+12,245
| +98% | +$236K |
|
|
ACAT
2218
DELISTED
Arctic Cat Inc
ACAT
| $593K | ﹤0.01% |
17,853
-845
| -5% | -$29.4K |
|
2219
America's Car Mart
CRMT
$26.6M
| $591K | ﹤0.01% |
11,973
-200
| -2% | -$10.5K |
|
|
BFX
2220
DELISTED
BowFlex Inc.
BFX
| $591K | ﹤0.01% |
27,488
-7,015
| -20% | -$139K |
|
|
XLRN
2221
DELISTED
Acceleron Pharma
XLRN
| $591K | ﹤0.01% |
18,685
+3,215
| +21% | +$104K |
|
|
BKMU
2222
DELISTED
Bank Mutual Corp
BKMU
| $591K | ﹤0.01% |
77,029
-3,480
| -4% | -$25.4K |
|
|
ITCI
2223
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $590K | ﹤0.01% |
18,455
+3,500
| +23% | +$88.7K |
|
2224
Banc of California
BANC
$3.03B
| $588K | ﹤0.01% |
42,764
+670
| +2% | +$8.77K |
|
|
GBL
2225
DELISTED
GAMCO Investors, Inc.
GBL
| $582K | ﹤0.01% |
15,718
-919
| -6% | -$36.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2015 Portfolio in Review
As of Q2 2015, RhumbLine Advisers held 3,232 positions worth $31.4B, down 9.5% from $34.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
RhumbLine Advisers withdrew a net $3.23B in Q2 2015, closing 190 positions and reducing 1,615 holdings. Its most notable exit was LORILLARD INC COM STK, an estimated $34M position sold in full.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 15% a quarter earlier, followed by Healthcare and Technology.
Against the trend, RhumbLine Advisers opened a new position in COMCAST CORP SPL A (NEW) worth $11.8M.
- RhumbLine Advisers's largest Q2 2015 buy was COMCAST CORP SPL A (NEW): 197,055 shares worth $11.8M.
- RhumbLine Advisers added most to Aptiv in Q2 2015, an estimated $16.8M increase.
- RhumbLine Advisers's biggest Q2 2015 reduction was Apple, cutting an estimated $215M.
- RhumbLine Advisers fully exited LORILLARD INC COM STK in Q2 2015, selling an estimated $34M.
- RhumbLine Advisers's ten largest holdings make up 14% of its $31.4B portfolio in Q2 2015.
- RhumbLine Advisers opened 197 new positions and closed 190 in Q2 2015.
- RhumbLine Advisers's portfolio value fell 9.5% quarter-over-quarter to $31.4B.
Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.